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Acetaminophen (APAP) is used drugs worldwide for treating pain and fever. However, APAP overdose is
the principal cause of acute liver failure in Western countries. Salvianolic acid B (SalB), a major water-
soluble compound extracted from Radix Salvia miltiorrhiza, has well-known antioxidant and anti-
inﬂammatory actions. We aimed to evaluate the ability of SalB to protect against APAP-induced acute
hepatotoxicity by inducing nuclear factor-erythroid-2-related factor 2 (Nrf2) expression. SalB pretreat-
ment ameliorated acute liver injury caused by APAP, as indicated by blood aspartate transaminase levels
and histological ﬁndings. Moreover, SalB pretreatment increased the expression of Nrf2, Heme
oxygenase-1 (HO-1) and glutamate-L-cysteine ligase catalytic subunit (GCLC). Furthermore, the HO-1
inhibitor zinc protoporphyrin and the GCLC inhibitor buthionine sulfoximine reversed the protective
effect of SalB. Additionally, siRNA-mediated depletion of Nrf2 reduced the induction of HO-1 and GCLC by
SalB, and SalB pretreatment activated the phosphatidylinositol-3-kinase (PI3K) and protein kinase C
(PKC) signaling pathways. Both inhibitors (PI3K and PKC) blocked the protective effect of SalB against
APAP-induced cell death, abolishing the SalB-induced Nrf2 activation and decreasing HO-1 and GCLC
expression. These results indicated that SalB induces Nrf2, HO-1 and GCLC expression via activation of
the PI3K and PKC pathways, thereby protecting against APAP-induced liver injury.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.APAP, acetaminophen; ARE,
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Acute liver failure is a global disease that can be attributed to
various liver lesions. The major causes of acute liver failure are viral
infection, drug exposure, accidental food poisoning and radiation
damage (1,2). Acetaminophen (APAP) is widely used as an analgesic
and antipyretic agent; it is also known to induce liver injury, ac-
counting for the most common form of acute liver failure (3).
Toxicity is initiated by cytochrome P450-mediated metabolism of
APAP to the reactive metabolite N-acetyl-p-benzoquinoneimine
(NAPQI). The binding of NAPQI to cellular macromolecules induces
cellular oxidant stress and DNA damage, leading to severe cen-
trilobular hepatotoxicity and acute liver failure (4,5). Therefore,
designing therapies that inhibit oxidative stress and scavenge
electrophiles is expected to be one of the most important strategies
for treating APAP-induced liver injury.r B.V. All rights reserved.
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role in the induction of antioxidant enzymes via binding to anti-
oxidant response elements (AREs). This regulation can be grouped
into several categories according to the induction of phase II
detoxifying enzymes, antioxidant genes, scavenger receptor and
transporters (6). Furthermore, among the antioxidant and detoxi-
ﬁcation enzymes, Heme oxygenase-1 (HO-1) and glutamate-L-
cysteine ligase catalytic subunit (GCLC) are the most important.
Recent studies have shown that activation of Nrf2 plays an
important role in acute liver injury both in vitro and in vivo (7,8). To
date, multiple signaling kinases have been reported to regulate
Nrf2, including mitogen-activated protein kinase (MAPK), protein
kinase C (PKC) and phosphatidylinositol-3-kinase (PI3K) (9,10).
Salvianolic acid B (SalB) is the most abundant and bioactive
component of salvianolic acid extracted from Radix Salvia miltior-
rhiza, which is ofﬁcially listed in the Chinese Pharmacopoeia (11).
Previous research has demonstrated that SalB inhibits lipid per-
oxidation and scavenges superoxide anions and hydroxyl radicals
both in vitro and in vivo (12,13). There is evidence that treatment
with SalB reduces brain damage and improves motor function after
cerebral ischemia in rats (14,15). In addition, SalB has been reported
to protect against liver ﬁbrosis in patients and animals, as well as
inhibit CCl4-induced hepatic ﬁbrosis; these beneﬁcial effects are
associated with the regulation of NF-kB/I(k)B(a) signaling (16,17).
The above observations regarding the biological activities of
SalB compelled us to investigate whether SalB can attenuate APAP-
induced liver injury. The goals of this study were to investigate the
expression of Nrf2, HO-1 and GCLC in APAP-induced liver damage,
determine whether SalB up-regulates the expression of Nrf2, HO-1
and GCLC, and further elucidate whether PI3K and PKC are involved
in the regulation of Nrf2.
2. Materials and methods
2.1. Chemicals
SalB with a purity >98% was obtained from the Chinese National
Institute for the Control of Pharmaceutical and Biological Products
(Beijing, China). Acetaminophen and dimethyl sulfoxide were
purchased from SigmaeAldrich (St. Louis, MO, USA). Eagle's mini-
mum essential medium (MEM) and trypsin were purchased from
Gibco (Life Technologies, Carlsbad, CA, USA). RNase inhibitor and
DNA oligo were purchased from TaKaRa (Shiga, Japan). Inhibitors of
PI3K/AKT, ERK1/2, p38, JNK, PKC, PKCd and GCLC (LY294002,
PD98059, SB203580, SP600125 and GF109203X), as well as
buthionine sulfoximine (BSO), were acquired from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Zinc protoporphyrin (ZnPP)
was purchased from Alfa Aesar (Ward Hill, MA, USA).
2.2. Animals
Male Kunming mice, weighing 18e22 g, were provided by the
Animal Center of Dalian Medical University (Dalian, China). The
animals were fed standard chow and water, housed in plastic
cages and maintained at 22 ± 2 C with 50e60% relative humidity
and a 12-h lightedark cycle throughout the experiment. All
procedures were conducted according to the institutional animal
care guidelines and approved by the Institutional Ethics
Committee.
Animals were divided into ﬁve groups of ten animals per group.
Group 1 received vehicle (double-distilled water) only and served
as the normal control. Group 2 only received 50 mg/kg SalB (dis-
solved in double-distilled water) once a day for three days. Group 3
animals were intragastrically administered a single dose of APAP at
300 mg/kg (dissolved in double-distilled water at 37 C) and thenkept as the experimental model. Groups 4 and 5 received SalB at 25
and 50 mg/kg, respectively, once a day for three consecutive days.
Two hours after the last SalB pretreatment, the animals received an
intragastric dose of APAP. The experimental animals were sacri-
ﬁced, and blood samples were collected from the abdominal aorta
24 h after APAP administration. The serum was separated by
centrifugation at 3000 rpm/min for 30 min at 4 C. The liver was
collected from each mouse for biochemical, Western blot, and
histopathological analysis.
2.3. Cell culture
Well-differentiated human hepatoma cell line HepG2 has been
used to identify factors which regulate hepatic gene expression
during the host response to tissue injury (18). And in Guerrero JA
et.al study they found that using anoikis-hepatocytes from primary
culture and H2O2-treated HepG2 cells conﬁrmed the presence of a
similar complex (19). So in this study, we used HepG2 cells as our
model cells to explore the mechanism of SalB in APAP-induced
injury.
HepG2 cells were cultured inMEM supplementedwith 10% (v/v)
fetal bovine serum at 37 C in a 5% CO2 humidiﬁed incubator. Cells
seeded at a density of 1105 cells per well were grown for 24 h and
then treated with SalB at various concentrations (0.5, 2, 8 mmol/L).
Each experimental protocol is described in the corresponding
ﬁgure legends.
2.4. Biochemical index assay
Serum alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) represent the liver function along with disease
and are the most commonly used biochemical markers. Mouse
serum ALT and AST levels in liver tissues were measured using an
assay kit (Nanjing Jiancheng Corp., Nanjing, China) according to the
manufacturer's recommendations.
2.5. Histopathological evaluation
Fresh hepatic samples were ﬁxed in 10% neutral formalin for
24e48 h before being embedded in parafﬁn. After embedding, the
samples were cut into 5-mm sections and mounted onto slides.
Duplicate sections were stained with hematoxylin and eosin (H&E)
for pathological evaluation.
2.6. Western blot analysis
Cytoplasmic and nuclear proteins were extracted from HepG2
cells or liver tissue using a protein extraction kit (KeyGen Biotech,
Nanjing, China). Extracted proteins were separated using SDS-PAGE
and immunoblotted with the indicated primary antibodies. The
blots were then incubated with secondary antibodies. The mem-
branes were exposed to enhanced chemiluminescence-plus re-
agents (Beyotime Institute of Biotechnology, Hangzhou, China),
documented using a BioSpectrum-410 multispectral imaging sys-
tem with a Chemi HR camera 410 and analyzed using the Gel-Pro
Analyzer, version 4.0 (Media Cybernetics, Rockville, MD, USA).
2.7. RNA isolation and RT-PCR
Total RNAwas extracted from HepG2 cells using TRIZOL reagent
(Invitrogen, Carlsbad, CA, USA). Reverse transcription was per-
formed using the TaKaRa RNA PCR Kit (AMV) Version 3.0 (TaKaRa,
Shiga, Japan). For PCR analysis, the primers and their sequences
were reported in our previous study (20). The co-ampliﬁed PCR
products were separated on a 1.5% agarose gel using
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with a Chemi HR camera 410 (UVP Inc., Upland, CA, USA) was used
to analyze the intensity of the DNA bands.
2.8. Transient transfection and RNA interference
HepG2 cells were transfected with speciﬁc siRNA at a concen-
tration of 100 nM using Lipofectamine™ 2000 reagent (Invi-
trogen) according to the manufacturer's instructions. Human Nrf2
siRNA was obtained from Genepharma Technology (Shanghai,
China). After siRNA transfection, cells were incubated with fresh
culture medium containing 8 mM SalB. The protein extracts made
from the siRNA transfection experiments were analyzed to
determine the expression of HO-1, GCLC, and Nrf2 via Western
blotting.
2.9. Statistical analysis
Data are expressed as the mean ± SD. The signiﬁcance of the
differences among the mean values was evaluated using one-wayFig. 1. Effect of SalB on APAP-induced liver injury. Mice pretreated with SalB (25 or 50 mg/k
were sacriﬁced 24 h after APAP administration. (A) The activity of ALT and AST from serum
double-distilled water (DDS) were tested controls. (b) Mice treated with 50 mg/kg SalB. (c)
liver injury. Values are expressed as means ± SD, n ¼ 10. **p < 0.01 vs. the control group;analysis of variance. The Student-Newman-Keuls (SNK)/least sig-
niﬁcant difference (LSD) test was applied to make pairwise com-
parisons among the means. Differences were considered
statistically signiﬁcant when the p value was less than 0.05. All
statistical analyses were performed using the SPSS16 statistical
software package (SPSS Inc., Chicago, IL, USA).3. Results
3.1. SalB protects against APAP-induced acute liver injury
We ﬁrst determined the protective effect of SalB against APAP-
induced hepatotoxicity in vivo. As shown in Fig. 1A, APAP alone
dramatically increased serum ALT and AST activity. However, when
animals also received SalB pretreatment, the serum ALT and AST
activity were signiﬁcantly decreased compared to those of the APAP
control. We further veriﬁed the protective effect of SalB by per-
forming a histopathological evaluation of the liver. As shown in
Fig. 1B, the vehicle produced no apparent abnormalities, whereas
APAP-induced a disordered arrangement of hepatocytes,g per day, i.g., for 3 days) received a single dose of APAP (300 mg/kg, i.g.). The animals
samples. (B) Hematoxylin and eosin staining of the liver (400). (a) Mice treated with
APAP-induced liver injury. (d) SalB (50 mg/kg) pretreatment suppressed APAP-induced
##p < 0.01 vs. the APAP group.
Fig. 3. Effect of selective HO-1 and GCLC inhibitors on HepG2 cell viability. HepG2 cells
were pretreated with 20 mM ZnPP or 200 mM BSO for 2 h and then treated with 8 mM
SalB for 6 h. Next, cells were further exposed to 10 mM APAP for 24 h to evaluate cell
viability. **p < 0.01 vs. the control group; ##p < 0.01 vs. the APAP group; &&p < 0.01 vs.
the SalB þ APAP group.
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Microscopic examination revealed that the severe hepatic lesions
induced by APAP were remarkably reduced by SalB pretreatment.
Liver injury was relieved and reversed with SalB pretreatment.
These results indicated that SalB prevents APAP-induced injury in a
mouse model.
3.2. SalB induces expression of Nrf2 and phase II enzyme genes
Cells can be protected from oxidative stress either by directly
scavenging ROS (reactive oxygen species) or by fortifying the body's
antioxidant defenses. Therefore, we determined whether the pro-
tective effect of SalB against liver injury is associated with Nrf2 and
phase II enzymes. In Fig. 2A, pretreatment of mice with SalB alone
increased Nrf2, HO-1 and GCLC protein expression compared with
that in vehicle controls. Moreover, pretreatment with SalB for 3
days before APAP administration signiﬁcantly increased Nrf2, HO-1
and GCLC protein expression compared with that in mice receiving
APAP. Additionally, we probed the effects of SalB on Nrf2, HO-1 and
GCLC protein expression in vitro (Fig. 2B), which showed the same
results as that in vivo. Consistent with protein expression, the cor-
responding mRNA expression in vivo and in vitro displayed the
same trend (data not shown). To further investigate whether the
protective effects of SalB are associated with induction of HO-1 and
GCLC, we used speciﬁc HO-1 and GCLC inhibitors (ZnPP and BSO,
respectively). The inhibitors abrogated the protective effect of SalB
on HepG2 cells (Fig. 3). Taken together, these experiments sug-
gested that SalB protects the liver from APAP-induced injury
through induction of Nrf2, HO-1 and GCLC.
3.3. SalB-induced phase II enzyme expression is mediated by Nrf2
Given that most genes encoding phase II detoxifying and antiox-
idant enzymes contain an ARE, which has been reported as the
mechanism throughwhichNrf2 regulates transcription (21), we next
studiedwhetherNrf2 up-regulated the expression ofHO-1 andGCLC.Fig. 2. Effect of SalB on Nrf2, HO-1 and GCLC expression. (A) Effect of SalB on the protein le
with SalB (25 or 50 mg/kg per day, i.g., for 3 days) received a single dose of APAP (300 mg/k
protein levels of GCLC in HepG2 cells. Cells were pretreated with 0, 0.5, 2, or 8 mM SalB for 6
vs. the control group; ##p < 0.01 vs. the APAP group; &&p < 0.01 vs. the SalB þ APAP groupWe examined HO-1 and GCLC expression after siRNA knockdown of
Nrf2 in HepG2 cells. Silencing Nrf2 expression with speciﬁc siRNA
abolished SalB-induced up-regulation of HO-1 and GCLC, whereas
Nrf2 expression was not affected in the control siRNA group (Fig. 4).
These results suggest that the SalB-induced expression of HO-1 and
GCLC is regulated by the activation of Nrf2 signaling.3.4. SalB enhances Nrf2-mediated phase II enzyme expression via
activation of PI3K/AKT and PKC signaling
Several signaling pathways, including the MAPK, PI3K/AKT, and
PKC pathways, are involved in the induction of Nrf2 activation
(22,23). To elucidate the upstream signaling events leading to Nrf2vels of Nrf2, HO-1 and GCLC during APAP-induced liver injury in mice. Mice pretreated
g, i.g.). The animals were killed 24 h after APAP administration. (B) Effect of SalB on the
h. Values are expressed as means ± SD, n ¼ 3. *p < 0.05 vs. the control group; **p < 0.01
.
Fig. 4. Involvement of Nrf2 in SalB-induced HO-1 and GCLC expression. HepG2 cells were transfected with a Nrf2 siRNA or control siRNA for 6 h, followed by treatment with 8 mM
SalB for an additional 42 h. Nrf2, HO-1 and GCLC were evaluated using Western blotting. Values are expressed as means ± SD, n ¼ 3. **p < 0.01 vs. the si-control group.
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used: GF109203X (for PKC), LY294002 (for PI3K), PD98059 (for
extracellular signal-related protein kinases 1/2 (ERK1/2)),
SB203580 (for P38), and SP600125 (for c-Jun N-terminal kinase
(JNK)). The results indicated that inhibiting PI3K with LY294002 or
the PKC pathways with GF109203X blocked the protective effect of
SalB against cell death induced by APAP; however, the other in-
hibitors did not show this effect (Fig. 5A).
To further elucidate the roles of PKC and PI3K signaling in SalB-
induced Nrf2 activation, we examined the effects of SalB on the
activation of PKC and AKT, a PI3K downstream target. SalB signiﬁ-
cantly increased the protein phosphorylation levels of AKTand PKC,
whereas no difference was found in the phosphorylation of ERK,
P38 and JNK proteins (Fig. 5B). To further elucidate the molecular
mechanism underlying Nrf2 activation, we attempted to determine
the link between PI3K/AKT, PKC and Nrf2 activation induced by
SalB. Interestingly, speciﬁcally inhibiting PI3K/AKT and PKC
apparently abolished the ability of SalB to increase Nrf2, HO-1 andFig. 5. Effect of selective kinase inhibitors on cell viability and protein expression in the pres
LY294002, 20 mM PD98059, 20 mM SB203580 or 20 mM SP600125 for 1 h and then treated
Values are expressed as means ± SD, n ¼ 10. ** p < 0.01 vs. the control group; ## p < 0.01 vs. t
phosphorylation levels of AKT, PKC, ERK, P38, and JNK. Cells treated with 0, 0.5, 2, or 8 mM S
blotting. Values are expressed as means ± SD, n ¼ 3.GCLC expression (Fig. 6A and B). These data indicated that PI3K/AKT
and PKC are candidate kinases for the regulation of Nrf2, HO-1 and
GCLC expression induced by SalB (Fig. 7).
4. Discussion
Radix Salvia miltiorrhiza is one of the most important traditional
herbal medicines and is widely used to treat coronary artery dis-
ease, cardiovascular diseases and liver ﬁbrosis (14,24). SalB, the
most abundant and bioactive ingredient of Radix Salvia miltiorrhiza,
has raised considerable interest in recent years. Previous in-
vestigations have reported that SalB possesses hepatoprotective
effects (15,25). SalB suppresses TGF-b1 expression, decreases MAPK
activity and effectively reverses the effects of liver ﬁbrosis during
chronic hepatitis B. In a study by Kong R et al, it was shown that
SalB pretreatment protected liver tissue against ischemia-
reperfusion injury through decreased post-ischemic oxidative
stress, improved energy metabolism, and reduced hepatocellularence of SalB. (A) Cell viability of HepG2 cells pretreated with 20 mM GF109203X, 20 mM
with 8 m M SalB for 6 h. The cells were then further exposed to 10 mM APAP for 24 h.
he APAP group; && p < 0.01 vs. the SalB þ APAP group. (B) Effect of SalB on the total and
alB for 6 h. Phosphorylated AKT, PKC, ERK, P38 and JNK were evaluated using Western
Fig. 6. The roles of PKC and PI3K signaling in SalB-induced Nrf2, HO-1 and GCLC expression. HepG2 cells were pretreated with 20 mM GF109203X or 20 mM LY294002 for 1 h and
then treated with 8 mM SalB for 6 h. AKT, PKC, Nrf2, HO-1 and GCLC levels were assessed using Western blotting. PKC, Nrf2, HO-1 and GCLC levels were assessed using Western
blotting. Values are expressed as means ± SD, n ¼ 3. **p < 0.01 vs. the control group.
M. Lin et al. / Journal of Pharmacological Sciences 127 (2015) 203e210208apoptosis (26). SalB was also reported to protect against platelet-
derived growth factor (PDGF)-induced cell proliferation and
migration, and these beneﬁcial effects are associated with the in-
duction of HO-1 via Nrf2 activation (27). In the present study, for
the ﬁrst time, we reported that SalB clearly protects hepatocytes
against APAP-induced damage. The protective effect is mainly
associated with up-regulation of HO-1 and GCLC expressionFig. 7. Scheme summarizing the inhibition of APAP-induced liver injury by SalB via the
up-regulation of Nrf2, HO-1 and GCLC expression through the PI3K and PKC pathways.through the activation of Nrf2 translocation and the stimulation of
the PI3K/AKT and PKC pathways.
Numerous studies have shown that administering natural
compounds to induce phase II enzymes is sufﬁcient to promote
antioxidant and protective activities. It is generally known that HO-
1 and GCLC are principal phase II enzymes. HO-1 is induced as a
protective mechanism in response to various stimuli. HO-1 over-
expression has been demonstrated to protect against ethanol-
induced apoptosis (28). By contrast, suppression of HO-1 activity
results in increased hepatocellular injury, apoptosis, and death
from infection/sepsis in mice (29). In addition, certain HO-1 in-
ducers have the potential to protect hepatocytes against oxidative
injury (30). GCLC is the rate-limiting enzyme in the synthesis of
glutathione, a major antioxidant molecule in cells. Previous studies
have shown that oleanolic acid lessens APAP-induced cellular
damage by up-regulating GCLC expression (31). Consistent with
these observations, in the present study, we found that SalB-
induced HO-1 and GCLC expression in liver tissue and HepG2 cells
(Fig. 2). More importantly, the protective effect of SalB against APAP
injury in HepG2 cells was attenuated by the HO-1 inhibitor ZnPP
and the GCLC inhibitor BSO, suggesting that the former effect is
associated with HO-1 and GCLC (Fig. 3).
Induction of HO-1 and GCLC is mainly due to transcriptional
activation mediated by Nrf2 through its interaction with ARE reg-
ulatory DNA elements (32,33). Additionally, Nrf2 target genes have
been shown to be involved in the detoxiﬁcation of highly reactive
intermediates; therefore, the substance that activates Nrf2 might
be a good candidate target for protecting against APAP-induced
hepatotoxicity. In the present study, we found that SalB up-
M. Lin et al. / Journal of Pharmacological Sciences 127 (2015) 203e210 209regulated Nrf2 expression in vivo and in vitro. To determine the
involvement of Nrf2 in SalB-induced HO-1 and GCLC expression, we
used RNA interference directed against Nrf2. The results indicated
that silencing Nrf2 with siRNA abolished SalB-induced Nrf2, HO-1
and GCLC protein expression (Fig. 4), suggesting that the SalB-
induced up-regulation of HO-1 and GCLC depends on increased
nuclear expression of Nrf2.
It has been reported that mice administration of APAP could
increase cytoprotective genes, including Nrf2, NADPH quinone
oxidoreductase 1 (Nqo1) and GCLC, which may provide insight into
adaptive recovery mechanisms and development of resistance of
cytotoxic xenobiotics (34). Combined with the previous results, we
also found that APAP itself increased Nrf2, HO-1 and GCLC protein
expression, which suggested that cellular defense is able to act in
concert to resist harmful reactive intermediates formed from APAP
in a certain extent. In other words, increased Nrf2, HO-1 and GCLC
expression is an adaptive response to APAP-induced hepatitis.
Several cytosolic kinases, such asMAPK, PI3K/AKT and PKC, have
been shown to modulate Nrf2 and participate in signal trans-
duction from antioxidants and xenobiotics to ARE (35,36). ERK, JNK,
and p38 are the primary members of the MAPK family. We there-
fore observed the effects of SalB on the expression levels of MAPKs,
PI3K/AKT and PKC. Our results suggested that AKT and PKC but not
p38, JNK or ERK are mainly activated in the presence of SalB
(Fig. 5B). Our observations therefore support the hypothesis that
PI3K/AKT and PKC play an important role in the protective effect of
SalB against liver injury induced by APAP overdose. In the present
study, we demonstrated that the PI3K/AKT inhibitor LY293002 and
the PKC inhibitor GF109203X alleviated the cytoprotective effect of
SalB against APAP-induced cell death (Fig. 5A). Consequently, we
concluded that SalB triggers PI3K and PKC signaling to activate the
Nrf2 signaling pathway, a process that is, at least in part, respon-
sible for the protective effect against APAP-induced hepatotoxicity.
In summary, we demonstrated for the ﬁrst time that SalB pro-
tects the liver from APAP-induced injury by up-regulating HO-1
and GCLC expression via the activation of Nrf2 nuclear trans-
location and that the PI3K/AKT and PKC pathways are involved in
this process. These ﬁndings provide a rationale for potential clinical
applications of SalB for the prevention or treatment of liver
intoxication.Conﬂict of interest
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